DE102006007249B4 - Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2 - Google Patents

Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2 Download PDF

Info

Publication number
DE102006007249B4
DE102006007249B4 DE102006007249A DE102006007249A DE102006007249B4 DE 102006007249 B4 DE102006007249 B4 DE 102006007249B4 DE 102006007249 A DE102006007249 A DE 102006007249A DE 102006007249 A DE102006007249 A DE 102006007249A DE 102006007249 B4 DE102006007249 B4 DE 102006007249B4
Authority
DE
Germany
Prior art keywords
mrna
tumor
bladder
seq
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102006007249A
Other languages
German (de)
English (en)
Other versions
DE102006007249A1 (de
Inventor
Jens M. Dr. Warnecke
Merle Hanke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schleswiger Tauwerkfabrik Oellerking GmbH and Co KG
Universitatsklinikum Schleswig Holstein UKSH
Universitaet zu Luebeck
Original Assignee
Schleswiger Tauwerkfabrik Oellerking GmbH and Co KG
Universitatsklinikum Schleswig Holstein UKSH
Universitaet zu Luebeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schleswiger Tauwerkfabrik Oellerking GmbH and Co KG, Universitatsklinikum Schleswig Holstein UKSH, Universitaet zu Luebeck filed Critical Schleswiger Tauwerkfabrik Oellerking GmbH and Co KG
Priority to DE102006007249A priority Critical patent/DE102006007249B4/de
Publication of DE102006007249A1 publication Critical patent/DE102006007249A1/de
Application granted granted Critical
Publication of DE102006007249B4 publication Critical patent/DE102006007249B4/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE102006007249A 2006-02-15 2006-02-15 Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2 Expired - Fee Related DE102006007249B4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102006007249A DE102006007249B4 (de) 2006-02-15 2006-02-15 Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006007249A DE102006007249B4 (de) 2006-02-15 2006-02-15 Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2

Publications (2)

Publication Number Publication Date
DE102006007249A1 DE102006007249A1 (de) 2007-08-30
DE102006007249B4 true DE102006007249B4 (de) 2008-07-31

Family

ID=38319621

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102006007249A Expired - Fee Related DE102006007249B4 (de) 2006-02-15 2006-02-15 Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2

Country Status (1)

Country Link
DE (1) DE102006007249B4 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034385A1 (en) 2016-07-21 2018-01-25 The General Hospital Corporation Extracellular mrna markers of muscular dystrophies in human urine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002015770A2 (en) * 2000-08-18 2002-02-28 Digene Corporation Methods of cancer prognosis and assessment
US20040038240A1 (en) * 2001-07-13 2004-02-26 Akhouri Sinha Method and materials for assessing cancer aggressiveness
WO2004033641A2 (en) * 2002-10-04 2004-04-22 Sloan Kettering Institute For Cancer Research Gene expression profiling of bladder cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002015770A2 (en) * 2000-08-18 2002-02-28 Digene Corporation Methods of cancer prognosis and assessment
US20040038240A1 (en) * 2001-07-13 2004-02-26 Akhouri Sinha Method and materials for assessing cancer aggressiveness
WO2004033641A2 (en) * 2002-10-04 2004-04-22 Sloan Kettering Institute For Cancer Research Gene expression profiling of bladder cancer

Also Published As

Publication number Publication date
DE102006007249A1 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
DE19829473C2 (de) Verfahren zur frühen Diagnose von Carcinomen
DE60030281T2 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
DE602004008889T2 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
DE60105411T2 (de) Verfahren zur diagnose von krebs
EP1786929B1 (de) Verfahren zur diagnose von eierstockkrebs
EP3184646B1 (de) Spezifische signaturen in alzheimer durch multizentrische mirna-profile
DE102005052384B4 (de) Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
DE69737812T2 (de) Diagnose durch Bestimmung von Polymorphismen in der Promoterregion des TGF-Beta 1 Gens
DE102015208083B3 (de) Verfahren zur Prognose und/oder Diagnose einer Krankheit auf Basis von einer Probe aus Fettgewebe und Kit für dieses Verfahren
DE102006007249B4 (de) Verfahren zur Bestimmung von Blasenkarzinomen des Differenzierungsgrades G2
EP1453531B1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
EP3397773B1 (de) Verfahren und mittel zur diagnostik von tumoren
EP2092087A2 (de) Prognostische marker für die klassifizierung von kolorektalen karzinomen basierend auf expressionsprofilen von biologischen proben
EP2430182A1 (de) Diagnostische marker für die bestimmung der prädisposition der entwicklung von gebärmutterhalskrebs und für die bestimmung eingesetzte oligonukleotide
DE102006032394B4 (de) Verfahren zur Diagnose und Differenzierung von Prostatakrebs
DE102017214449B4 (de) Verfahren und Mittel zur Diagnostik von Tumoren durch Nachweis und Quantifizierung heterogen methylierter Epiallele
DE10337368A1 (de) Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
EP1514115A2 (de) Diagnostikum und nachweisverfahren für ein karzinom und mittel zu seiner behandlung
DE102020102143B3 (de) Verfahren zur Bestimmung, ob eine Behandlung einer Krebserkrankung begonnen oder fortgesetzt werden soll, ein Biomarker, der mindestens einem Markergen entspricht, und eine Verwendung des Biomarkers in dem erfindungsgemäßen Verfahren
DE102007048636B4 (de) Marker zur Diagnose von Krebs
WO2004076613A2 (de) Humane nukleinsäuresequenzen aus harnblasenkarzinomen
WO2008061525A2 (de) Prognostische marker für die klassifizierung des dreijährigen progressionsfreien überlebens von patienten mit kolorektalem karzinom basierend auf expressionsprofilen von biologischen proben
DE102009015784A1 (de) In-vitro-Verfahren zur Diagnostik von Tumorerkrankungen
EP4031684A1 (de) Verfahren zur bestimmung der zellzahl mittels einer referenz-dna
EP1404874A2 (de) Screening-verfahren zur identifikation von krebstherapie-relevanten verbindungen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8364 No opposition during term of opposition
R082 Change of representative

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20140902